Last edition
News about "setmelanotide "
FDA Approves Rhythm Pharma's IMCIVREE for Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals has received US Food and Drug Administration (FDA) approval for IMCIVREE, the first and only treatment for acquired Hypothalamic Obesity (HO), supported by phase-III data showing a 18.4 percent placebo-adjusted BMI reduction in patients aged four years and older.
Setmelanotide | 20/03/2026 | By News Bureau
Rhythm Pharma Presents Patient-Reported Experiences with Hyperphagia at ENDO 2024
Rhythm Pharmaceuticals, Inc. has presented the first patient and caregiver reported experiences from qualitative interviews following the completion of a Phase 2 trial.
Setmelanotide | 04/06/2024 | By Aishwarya | 493
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy